DEFA14A: ProAssurance to be Acquired by The Doctors Company for $1.3 Billion, Creating Medical Malpractice Insurance Giant

ProAssurance Corporation has entered into an agreement to be acquired by The Doctors Company, creating the second-largest medical malpractice insurance company in the United States.

Summary

• ProAssurance has agreed to be acquired by The Doctors Company in a deal valued at approximately $1.3 billion, or $25 per share.
• The merger will create the second-largest medical malpractice insurance company in the U.S., with pro forma MPL direct written premiums of approximately $2 billion.
• The transaction has been approved by ProAssurance's Board of Directors and is expected to close in the first half of 2026.
• The deal is subject to shareholder and regulatory approvals, including antitrust clearance.
• Until the transaction closes, ProAssurance and The Doctors Company will continue to operate as separate companies.
• The combined company aims to leverage the strengths of both organizations to better serve healthcare providers and distribution partners.
• The Doctors Company has $7.3 billion in assets and member surplus of over $2.8 billion.
• ProAssurance shareholders will have the opportunity to vote on the transaction at a special meeting in the coming months.
• Post-close, ProAssurance will become a wholly-owned subsidiary of The Doctors Company.
• Integration plans will be developed by the senior leadership teams of both companies to ensure continued quality service and support to customers.

Sentiment

Score: 7

Explanation: The document conveys a generally positive sentiment, emphasizing the strategic advantages and benefits of the merger. However, it also acknowledges potential risks and uncertainties associated with the transaction, preventing a higher score.

Positives

• The merger creates a stronger, more financially stable organization to face challenges like social inflation and shock verdicts.
• The combined company will offer a broader range of capabilities and opportunities for growth for team members.
• The Doctors Company has a strong commitment to employee experience and an inclusive corporate culture.
• The transaction is expected to benefit distribution partners and healthcare clients.
• The Doctors Company's Tribute Plan rewards physicians for loyalty and dedication to patient care, with over $175 million awarded to date.
• Eastern Alliance is expected to provide similar value to The Doctors Company, which currently offers workers compensation coverages from other carriers through their agency.

Negatives

• There is uncertainty regarding the integration process and potential impacts on employees, office locations, and remote work practices.
• The transaction is subject to regulatory and shareholder approvals, and there is a risk that it may not be completed.
• There is potential for disruption to business relationships during the pendency of the transaction.
• The ProAssurance stock price may fluctuate during the pendency of the proposed transaction and may decline if the proposed transaction is not completed.

Risks

• The completion of the proposed transaction is subject to various conditions, including shareholder and regulatory approvals.
• Potential litigation relating to the proposed transaction could be instituted against ProAssurance or its directors, managers or officers.
• Disruptions from the proposed transaction could harm ProAssurance's business, including current plans and operations.
• There is a risk that ProAssurance may not be able to retain and hire key personnel.
• Management's time and attention may be diverted from ordinary course business operations to completion of the proposed transaction and integration matters.
• Potential adverse reactions or changes to business relationships may result from the announcement or completion of the proposed transaction.
• Legislative, regulatory and economic developments could impact the transaction.
• Business uncertainty during the pendency of the proposed transaction could affect ProAssurance's financial performance.
• Restrictions during the pendency of the proposed transaction may impact ProAssurance's ability to pursue certain business opportunities or strategic transactions.
• Unexpected costs, liabilities or delays may be associated with the transaction.
• The response of competitors to the transaction is uncertain.
• The occurrence of any event, change or other circumstance could give rise to the termination of the proposed transaction.

Future Outlook

The combined company aims to be the premier medical malpractice company, offering a broader range of products, defense expertise, and risk management services to healthcare providers and distribution partners.

Management Comments

• Ned Rand stated that the transaction is an affirmation of ProAssurance's efforts to transform in the face of challenges and that The Doctors Company is the ideal partner to take them into the future.
• Ned Rand committed to transparency and regular communication throughout the approval process.
• Kevin Shook assured that Eastern will continue with its unwavering commitment to its agency partners, policyholders, injured workers and each other, both before and after the transaction is finalized.

Industry Context

The medical malpractice insurance industry is rapidly consolidating, and this merger positions the combined company as a major player in the market.

Comparison to Industry Standards

• The Doctors Company is already the second-largest MPL carrier in the U.S.
• The combined company will solidify their position at #2 with over $1.9 billion in MPL premium based on 2024 NAIC filings.
• The Doctors Company's Tribute Plan is an unrivaled financial benefit that rewards physicians for their loyalty and dedication to superior patient care.
• The Doctors Company is rated A by AM Best Company and Fitch Ratings.

Stakeholder Impact

• Shareholders will have the opportunity to vote on the transaction.
• Employees may experience changes in benefits and work environment after the transaction closes.
• Policyholders can expect a continuation of services at the same high standards.
• Agents and brokers will have their agreements reviewed post-close.
• Defense counsel will have file assignments and new file assignment processes reviewed post-close.

Next Steps

• ProAssurance will file a proxy statement with the SEC.
• ProAssurance will mail the definitive proxy statement to its stockholders.
• ProAssurance shareholders will vote on the transaction at a special meeting.
• The transaction will require approvals from various state regulators.
• The transaction will need antitrust clearance from the U.S. Department of Justice and Federal Trade Commission.
• Senior leadership teams of ProAssurance and The Doctors Company will participate in the development of the integration plans to be implemented after the transaction closes.

Key Dates

Keywords

ProAssurance, The Doctors Company, acquisition, merger, medical malpractice insurance, insurance, regulatory approval, shareholder approval, MPL, Eastern Alliance, Medmarc